Acute Coronary Syndrome | Telmisartan Versus Ramipril After Acute Coronary Syndrome
Acute Coronary Syndrome research study
What is the primary objective of this study?
The purpose of this study is to compare the antinflammatory and endothelial progenitor cell (EPC) mobilizing effect of Ramipril and Telmisartan in patients presenting with acute coronary syndrome
Who is eligible to participate?
Inclusion Criteria: - Biochemical evidence of myocardial infarction as indicated by elevation of cTnT, - presence of ECG ischemic changes, - angiographic evidence of a primary coronary event, such as plaque erosion and/or rupture, fissuring, or dissection at coronary angiography, - successful coronary revascularization of at least one culprit coronary vessel. Exclusion Criteria: - Age>80 years, current ACE inhibitor or ARB treatment, - ejection fraction <35%, infarction secondary to ischemia due to an imbalance of O2 supply and demand, - ECG abnormalities that could affect the recognition of ST segment shift, - recent or chronic infective or inflammatory diseases, - malignancy, and myocardial infarction, - surgery or trauma in the previous month.
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Acute Coronary Syndrome
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:TELMISARTAN80 mg daily
Drug:RAMIPRIL5 mg daily
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
RTwenty-five patients assigned to ramipril 5 mg daily
TTwenty-five patients assigned to Telmisartan 80 mg daily
Start Date: November 2007
Completed Date: November 2008
Phase: Phase 4
Primary Outcome: High sensitivity C-Reactive Protein
Secondary Outcome: Endothelial Progenitor Cells
Study sponsors, principal investigator, and references
Principal Investigator: Italo Porto, MD, PhD
Lead Sponsor: Catholic University of the Sacred Heart
Biasucci LM, Lombardi M, Piro M, Di Giannuario G, Liuzzo G, Crea F. Irbesartan significantly reduces C reactive protein concentrations after 1 month of treatment in unstable angina. Heart. 2005 May;91(5):670-1.
Liakishev AA. [Telmisartan, ramipril, or both in patients at high risk for vascular events. Results of the ONTARGET trial]. Kardiologiia. 2008;48(5):72. Russian.